Granisetron

Evidence Level: L5

Predicted Indications: 10

Granisetron

Pharmacist Assessment Report

Granisetron: From Chemotherapy-Associated Nausea and Vomiting to Manic Bipolar Affective Disorder

One-Sentence Summary

Granisetron is a selective 5-HT3 receptor antagonist marketed in Australia as an oral tablet (Kytril). The TxGNN model predicts it may be effective for manic bipolar affective disorder, but this is a model prediction only, with no clinical trials and no publications currently supporting it.

Quick Overview

Item	Content
Original Indication	Not recorded in the data compiled for this report
Predicted New Indication	Manic bipolar affective disorder
TxGNN Prediction Score	0.9962
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Granisetron is known to be a selective 5-HT3 receptor antagonist.

It has been hypothesised that 5-HT3 modulation may influence the dopaminergic and serotonergic signalling relevant to mood regulation. This link is speculative. The original indication was not recorded, so the relationship between the original and new indication cannot be assessed here.

The high TxGNN score (0.9962) is a computational prediction only. It is not backed by any trial or literature data.

Other predicted indications (all L5, all Hold):

Rank	Predicted Indication	TxGNN Score	Mechanistic Plausibility
2	Tourette syndrome	0.9952	Speculative. 5-HT3 antagonism may indirectly modulate dopaminergic circuits, and other agents in the class (e.g. ondansetron) have been explored.
3	Acute contagious conjunctivitis	0.9949	No clear rationale. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
4	Angioedema	0.9936	Weak. Granisetron does not target histamine or bradykinin pathways.
5	Allergic urticaria	0.9932	Weak. Serotonin may contribute to itch and mast cell responses.
6	Nephrogenic syndrome of inappropriate antidiuresis	0.9932	No plausible mechanism (AVPR2 gain-of-function).
7	Trichotillomania	0.9923	Speculative. Serotonergic dysregulation is implicated in the obsessive-compulsive spectrum.
8	Bronchitis	0.9918	No established mechanistic connection.
9	Cold urticaria	0.9910	Minor, indirect role of serotonin in mast cell-related itch.
10	Conjunctivitis	0.9909	No plausible mechanistic link.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 5898K	Kytril	Tablet 2 mg (as hydrochloride)	Not available in the compiled data

Safety Considerations

Knowledge-graph contraindication signals (from drug-disease edges in the TxGNN knowledge graph, not product label text): long QT syndrome, familial long QT syndrome, potassium deficiency disease, sudden cardiac arrest, and heart conduction disease. These point to a QT-prolongation and cardiac conduction concern and should be checked against the label.
Drug interactions: 100 interactions were identified in total (DDInter). Examples from the first 20 reviewed:
- Major: fentanyl, dextromethorphan, tramadol, alfentanil, almotriptan, sumatriptan, amiodarone, amisulpride, amitriptyline, anagrelide. Several of these involve QT prolongation or serotonergic effects.
- Moderate: abametapir (topical), abiraterone, dihydrocodeine, codeine, famotidine, formoterol, adenosine, salbutamol, alfuzosin, propofol.

Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications, as label data were not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone (L5). There are no registered trials or publications, the mechanistic link to mania is speculative, and the compiled data contain no label-based safety information. The knowledge-graph cardiac contraindication signals and the many major interactions add further caution.

To proceed, the following is needed:

The TGA Product Information, to confirm the approved indication, warnings and contraindications
Mechanism of action data (e.g. from DrugBank)
A systematic literature and trial registry search (including ANZCTR) for granisetron or 5-HT3 antagonists in bipolar mania
A mechanistic and preclinical rationale for mood-disorder use
A cardiac safety assessment (QT and conduction) for the target population, which often takes interacting psychotropic medicines
Route and formulation compatibility assessment for the proposed use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.